Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

205 ta ish

Ish: Viral modulation of the CXCL12/CXCR4/CXCR7 axis: mechanisms, impacts on immunity and oncogenesis, and therapeutic opportunities

  1. Sarlavhasiz

    Boshqa8 iqtibos
    ABI

  2. Sarlavhasiz

    Boshqa7 iqtibos
    ABI

  3. Dna Damage Response Alterations in Gastric Cancer: Knocking down a New Wall

    Angela Dalia Ricci, Alessandro Rizzo, Giovanni Brandi

    Maqola20214 iqtibos
    ABI

  4. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

    Beverly A. Teicher, Simon P. Fricker

    Sharh maqolaOchiq kirish20103 iqtibos
    ABI

  5. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment

    Raffaele De Luca, Luca Gianotti, Paolo Pedrazzoli +13

    Sharh maqola20223 iqtibos
    ABI

  6. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

    Matteo Santoni, Sebastiano Buti, Zin Myint +63

    Maqola20233 iqtibos
    ABI

  7. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway

    Zhongxing Liang, Joann Brooks, Margaret Willard +4

    MaqolaOchiq kirish20072 iqtibos
    ABI

  8. CXCR4: A virus’s best friend?

    Kathleen L. Arnolds, Juliet V. Spencer

    Sharh maqolaOchiq kirish20142 iqtibos
    ABI

  9. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

    Xueqing Sun, Guangcun Cheng, Mingang Hao +6

    Sharh maqolaOchiq kirish20102 iqtibos
    ABI

  10. Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment

    Stefania Scala

    Sharh maqola20152 iqtibos
    ABI

  11. Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>

    Katia Beider, Merav Darash‐Yahana, Orly Blaier +8

    Maqola20142 iqtibos
    ABI

  12. Small Molecule Inhibitors of CXCR4

    Bikash Debnath, Shili Xu, Fedora Grande +2

    Sharh maqolaOchiq kirish20132 iqtibos
    ABI

  13. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors

    Anneleen Van Hout, Thomas D’huys, Merel Oeyen +2

    MaqolaOchiq kirish20172 iqtibos
    ABI

  14. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions

    Christine Huynh, Jasper Dingemanse, Henriette E. Meyer zu Schwabedissen +1

    Sharh maqolaOchiq kirish20202 iqtibos
    ABI

  15. The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

    Yi Shi, David J. Riese, Jianzhong Shen

    Sharh maqolaOchiq kirish20202 iqtibos
    ABI

  16. CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications

    Yaru Yang, Jiayan Li, Wangrui Lei +10

    Sharh maqolaOchiq kirish20232 iqtibos
    ABI

  17. Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19

    R. Alon, Mike Sportiello, Stav Kozlovski +5

    Sharh maqola20202 iqtibos
    ABI

  18. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies

    Sara K. Daniel, Yongwoo David Seo, Venu G. Pillarisetty

    Sharh maqola20192 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  20. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches

    Muhammad Tufail, Canhua Jiang, Ning Li

    Sharh maqola20252 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa1 iqtibos
    ABI